#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0059] On completion of hydrolytic cleavage of the glycosidic bond of the beta-D-galactopyranoside, formation and precipitation of the water-insoluble dye occur.
1-1	0-1	[	_	_	
1-2	1-5	0059	_	_	
1-3	5-6	]	_	_	
1-4	7-9	On	_	_	
1-5	10-20	completion	_	_	
1-6	21-23	of	_	_	
1-7	24-34	hydrolytic	_	_	
1-8	35-43	cleavage	_	_	
1-9	44-46	of	_	_	
1-10	47-50	the	_	_	
1-11	51-61	glycosidic	_	_	
1-12	62-66	bond	_	_	
1-13	67-69	of	_	_	
1-14	70-73	the	_	_	
1-15	74-98	beta-D-galactopyranoside	_	_	
1-16	98-99	,	_	_	
1-17	100-109	formation	_	_	
1-18	110-113	and	_	_	
1-19	114-127	precipitation	_	_	
1-20	128-130	of	_	_	
1-21	131-134	the	_	_	
1-22	135-150	water-insoluble	_	_	
1-23	151-154	dye	_	_	
1-24	155-160	occur	_	_	
1-25	160-161	.	_	_	

#Text=The dye is precipitated in the region of lipophilic structures, e.g. in the region of the lysed cells, cell membranes, etc. that are on the support, so that these regions on the support are colored.
2-1	162-165	The	_	_	
2-2	166-169	dye	_	_	
2-3	170-172	is	_	_	
2-4	173-185	precipitated	_	_	
2-5	186-188	in	_	_	
2-6	189-192	the	_	_	
2-7	193-199	region	_	_	
2-8	200-202	of	_	_	
2-9	203-213	lipophilic	_	_	
2-10	214-224	structures	_	_	
2-11	224-225	,	_	_	
2-12	226-229	e.g	_	_	
2-13	229-230	.	_	_	
2-14	231-233	in	_	_	
2-15	234-237	the	_	_	
2-16	238-244	region	_	_	
2-17	245-247	of	_	_	
2-18	248-251	the	_	_	
2-19	252-257	lysed	_	_	
2-20	258-263	cells	_	_	
2-21	263-264	,	_	_	
2-22	265-269	cell	_	_	
2-23	270-279	membranes	_	_	
2-24	279-280	,	_	_	
2-25	281-284	etc	_	_	
2-26	284-285	.	_	_	
2-27	286-290	that	_	_	
2-28	291-294	are	_	_	
2-29	295-297	on	_	_	
2-30	298-301	the	_	_	
2-31	302-309	support	_	_	
2-32	309-310	,	_	_	
2-33	311-313	so	_	_	
2-34	314-318	that	_	_	
2-35	319-324	these	_	_	
2-36	325-332	regions	_	_	
2-37	333-335	on	_	_	
2-38	336-339	the	_	_	
2-39	340-347	support	_	_	
2-40	348-351	are	_	_	
2-41	352-359	colored	_	_	
2-42	359-360	.	_	_	

#Text=The coloration can be detected by visual inspection.
3-1	361-364	The	_	_	
3-2	365-375	coloration	_	_	
3-3	376-379	can	_	_	
3-4	380-382	be	_	_	
3-5	383-391	detected	_	_	
3-6	392-394	by	_	_	
3-7	395-401	visual	_	_	
3-8	402-412	inspection	_	_	
3-9	412-413	.	_	_	

#Text=The coloration indicates the presence of the target DNA sequence in the cells applied to the support.
#Text=[0060] The methods described above can be used in particular for the identification of an unknown nucleotide at a predetermined position of an otherwise known DNA sequence, for example in the detection of a single nucleotide polymorphism in the chromosomal DNA of humans and of nonhuman mammals.
4-1	414-417	The	_	_	
4-2	418-428	coloration	_	_	
4-3	429-438	indicates	_	_	
4-4	439-442	the	_	_	
4-5	443-451	presence	_	_	
4-6	452-454	of	_	_	
4-7	455-458	the	_	_	
4-8	459-465	target	_	_	
4-9	466-469	DNA	_	_	
4-10	470-478	sequence	_	_	
4-11	479-481	in	_	_	
4-12	482-485	the	_	_	
4-13	486-491	cells	_	_	
4-14	492-499	applied	_	_	
4-15	500-502	to	_	_	
4-16	503-506	the	_	_	
4-17	507-514	support	_	_	
4-18	514-515	.	_	_	
4-19	516-517	[	_	_	
4-20	517-521	0060	_	_	
4-21	521-522	]	_	_	
4-22	523-526	The	_	_	
4-23	527-534	methods	_	_	
4-24	535-544	described	_	_	
4-25	545-550	above	_	_	
4-26	551-554	can	_	_	
4-27	555-557	be	_	_	
4-28	558-562	used	_	_	
4-29	563-565	in	_	_	
4-30	566-576	particular	_	_	
4-31	577-580	for	_	_	
4-32	581-584	the	_	_	
4-33	585-599	identification	_	_	
4-34	600-602	of	_	_	
4-35	603-605	an	_	_	
4-36	606-613	unknown	_	_	
4-37	614-624	nucleotide	_	_	
4-38	625-627	at	_	_	
4-39	628-629	a	_	_	
4-40	630-643	predetermined	_	_	
4-41	644-652	position	_	_	
4-42	653-655	of	_	_	
4-43	656-658	an	_	_	
4-44	659-668	otherwise	_	_	
4-45	669-674	known	_	_	
4-46	675-678	DNA	_	_	
4-47	679-687	sequence	_	_	
4-48	687-688	,	_	_	
4-49	689-692	for	_	_	
4-50	693-700	example	_	_	
4-51	701-703	in	_	_	
4-52	704-707	the	_	_	
4-53	708-717	detection	_	_	
4-54	718-720	of	_	_	
4-55	721-722	a	_	_	
4-56	723-729	single	_	_	
4-57	730-740	nucleotide	_	_	
4-58	741-753	polymorphism	_	_	
4-59	754-756	in	_	_	
4-60	757-760	the	_	_	
4-61	761-772	chromosomal	_	_	
4-62	773-776	DNA	_	_	
4-63	777-779	of	_	_	
4-64	780-786	humans	_	_	
4-65	787-790	and	_	_	
4-66	791-793	of	_	_	
4-67	794-802	nonhuman	_	_	
4-68	803-810	mammals	_	_	
4-69	810-811	.	_	_	

#Text=Single nucleotide polymorphisms (SNP) are the commonest sequence variations occurring in mammals.
5-1	812-818	Single	_	_	
5-2	819-829	nucleotide	_	_	
5-3	830-843	polymorphisms	_	_	
5-4	844-845	(	_	_	
5-5	845-848	SNP	_	_	
5-6	848-849	)	_	_	
5-7	850-853	are	_	_	
5-8	854-857	the	_	_	
5-9	858-867	commonest	_	_	
5-10	868-876	sequence	_	_	
5-11	877-887	variations	_	_	
5-12	888-897	occurring	_	_	
5-13	898-900	in	_	_	
5-14	901-908	mammals	_	_	
5-15	908-909	.	_	_	

#Text=In a single nucleotide polymorphism there is replacement of an individual nucleotide in a particular segment of a DNA molecule (e.g. a gene).
6-1	910-912	In	_	_	
6-2	913-914	a	_	_	
6-3	915-921	single	_	_	
6-4	922-932	nucleotide	_	_	
6-5	933-945	polymorphism	_	_	
6-6	946-951	there	_	_	
6-7	952-954	is	_	_	
6-8	955-966	replacement	_	_	
6-9	967-969	of	_	_	
6-10	970-972	an	_	_	
6-11	973-983	individual	_	_	
6-12	984-994	nucleotide	_	_	
6-13	995-997	in	_	_	
6-14	998-999	a	_	_	
6-15	1000-1010	particular	_	_	
6-16	1011-1018	segment	_	_	
6-17	1019-1021	of	_	_	
6-18	1022-1023	a	_	_	
6-19	1024-1027	DNA	_	_	
6-20	1028-1036	molecule	_	_	
6-21	1037-1038	(	_	_	
6-22	1038-1041	e.g	_	_	
6-23	1041-1042	.	_	_	
6-24	1043-1044	a	_	_	
6-25	1045-1049	gene	_	_	
6-26	1049-1050	)	_	_	
6-27	1050-1051	.	_	_	

#Text=In the human genome, a single nucleotide polymorphism is found roughly every 1000 base pairs.
7-1	1052-1054	In	_	_	
7-2	1055-1058	the	_	_	
7-3	1059-1064	human	_	_	
7-4	1065-1071	genome	_	_	
7-5	1071-1072	,	_	_	
7-6	1073-1074	a	_	_	
7-7	1075-1081	single	_	_	
7-8	1082-1092	nucleotide	_	_	
7-9	1093-1105	polymorphism	_	_	
7-10	1106-1108	is	_	_	
7-11	1109-1114	found	_	_	
7-12	1115-1122	roughly	_	_	
7-13	1123-1128	every	_	_	
7-14	1129-1133	1000	_	_	
7-15	1134-1138	base	_	_	
7-16	1139-1144	pairs	_	_	
7-17	1144-1145	.	_	_	

#Text=If this substitution is located in the coding region of a gene, it can result in an amino acid substitution in the encoded polypeptide.
8-1	1146-1148	If	_	_	
8-2	1149-1153	this	_	_	
8-3	1154-1166	substitution	_	_	
8-4	1167-1169	is	_	_	
8-5	1170-1177	located	_	_	
8-6	1178-1180	in	_	_	
8-7	1181-1184	the	_	_	
8-8	1185-1191	coding	_	_	
8-9	1192-1198	region	_	_	
8-10	1199-1201	of	_	_	
8-11	1202-1203	a	_	_	
8-12	1204-1208	gene	_	_	
8-13	1208-1209	,	_	_	
8-14	1210-1212	it	_	_	
8-15	1213-1216	can	_	_	
8-16	1217-1223	result	_	_	
8-17	1224-1226	in	_	_	
8-18	1227-1229	an	_	_	
8-19	1230-1235	amino	_	_	
8-20	1236-1240	acid	_	_	
8-21	1241-1253	substitution	_	_	
8-22	1254-1256	in	_	_	
8-23	1257-1260	the	_	_	
8-24	1261-1268	encoded	_	_	
8-25	1269-1280	polypeptide	_	_	
8-26	1280-1281	.	_	_	

#Text=Therefore the substitution of a single nucleotide can have serious physiological consequences for the individual in question.
9-1	1282-1291	Therefore	_	_	
9-2	1292-1295	the	_	_	
9-3	1296-1308	substitution	_	_	
9-4	1309-1311	of	_	_	
9-5	1312-1313	a	_	_	
9-6	1314-1320	single	_	_	
9-7	1321-1331	nucleotide	_	_	
9-8	1332-1335	can	_	_	
9-9	1336-1340	have	_	_	
9-10	1341-1348	serious	_	_	
9-11	1349-1362	physiological	_	_	
9-12	1363-1375	consequences	_	_	
9-13	1376-1379	for	_	_	
9-14	1380-1383	the	_	_	
9-15	1384-1394	individual	_	_	
9-16	1395-1397	in	_	_	
9-17	1398-1406	question	_	_	
9-18	1406-1407	.	_	_	

#Text=Single nucleotide polymorphisms have been described in connection with a number of diseases, for example in Alzheimer's disease, cystic fibrosis, mucoviscidosis, Duchenne's muscular dystrophy, Huntington's chorea, sickle cell anemia and malignant hyperthermia.
10-1	1408-1414	Single	_	_	
10-2	1415-1425	nucleotide	_	_	
10-3	1426-1439	polymorphisms	_	_	
10-4	1440-1444	have	_	_	
10-5	1445-1449	been	_	_	
10-6	1450-1459	described	_	_	
10-7	1460-1462	in	_	_	
10-8	1463-1473	connection	_	_	
10-9	1474-1478	with	_	_	
10-10	1479-1480	a	_	_	
10-11	1481-1487	number	_	_	
10-12	1488-1490	of	_	_	
10-13	1491-1499	diseases	_	_	
10-14	1499-1500	,	_	_	
10-15	1501-1504	for	_	_	
10-16	1505-1512	example	_	_	
10-17	1513-1515	in	_	_	
10-18	1516-1527	Alzheimer's	_	_	
10-19	1528-1535	disease	_	_	
10-20	1535-1536	,	_	_	
10-21	1537-1543	cystic	_	_	
10-22	1544-1552	fibrosis	_	_	
10-23	1552-1553	,	_	_	
10-24	1554-1568	mucoviscidosis	_	_	
10-25	1568-1569	,	_	_	
10-26	1570-1580	Duchenne's	_	_	
10-27	1581-1589	muscular	_	_	
10-28	1590-1599	dystrophy	_	_	
10-29	1599-1600	,	_	_	
10-30	1601-1613	Huntington's	_	_	
10-31	1614-1620	chorea	_	_	
10-32	1620-1621	,	_	_	
10-33	1622-1628	sickle	_	_	
10-34	1629-1633	cell	_	_	
10-35	1634-1640	anemia	_	_	
10-36	1641-1644	and	_	_	
10-37	1645-1654	malignant	_	_	
10-38	1655-1667	hyperthermia	_	_	
10-39	1667-1668	.	_	_	

#Text=Furthermore, single nucleotide polymorphisms play an important role in allergic drug reaction (e.g. to carbamazepine) and in Stevens-Johnson syndrome (toxic epidermal necrolysis).
11-1	1669-1680	Furthermore	_	_	
11-2	1680-1681	,	_	_	
11-3	1682-1688	single	_	_	
11-4	1689-1699	nucleotide	_	_	
11-5	1700-1713	polymorphisms	_	_	
11-6	1714-1718	play	_	_	
11-7	1719-1721	an	_	_	
11-8	1722-1731	important	_	_	
11-9	1732-1736	role	_	_	
11-10	1737-1739	in	_	_	
11-11	1740-1748	allergic	_	_	
11-12	1749-1753	drug	_	_	
11-13	1754-1762	reaction	_	_	
11-14	1763-1764	(	_	_	
11-15	1764-1767	e.g	_	_	
11-16	1767-1768	.	_	_	
11-17	1769-1771	to	_	_	
11-18	1772-1785	carbamazepine	_	_	
11-19	1785-1786	)	_	_	
11-20	1787-1790	and	_	_	
11-21	1791-1793	in	_	_	
11-22	1794-1809	Stevens-Johnson	_	_	
11-23	1810-1818	syndrome	_	_	
11-24	1819-1820	(	_	_	
11-25	1820-1825	toxic	_	_	
11-26	1826-1835	epidermal	_	_	
11-27	1836-1846	necrolysis	_	_	
11-28	1846-1847	)	_	_	
11-29	1847-1848	.	_	_	

#Text=Moreover, responsiveness to ovarian stimulation in reproductive medicine and to beta-adrenergic drugs in chronic obstructive lung disease is affected by single nucleotide polymorphisms.
#Text=[0061] A number of different methods of detecting single nucleotide polymorphisms are known in the prior art.
12-1	1849-1857	Moreover	_	_	
12-2	1857-1858	,	_	_	
12-3	1859-1873	responsiveness	_	_	
12-4	1874-1876	to	_	_	
12-5	1877-1884	ovarian	_	_	
12-6	1885-1896	stimulation	_	_	
12-7	1897-1899	in	_	_	
12-8	1900-1912	reproductive	_	_	
12-9	1913-1921	medicine	_	_	
12-10	1922-1925	and	_	_	
12-11	1926-1928	to	_	_	
12-12	1929-1944	beta-adrenergic	_	_	
12-13	1945-1950	drugs	_	_	
12-14	1951-1953	in	_	_	
12-15	1954-1961	chronic	_	_	
12-16	1962-1973	obstructive	_	_	
12-17	1974-1978	lung	_	_	
12-18	1979-1986	disease	_	_	
12-19	1987-1989	is	_	_	
12-20	1990-1998	affected	_	_	
12-21	1999-2001	by	_	_	
12-22	2002-2008	single	_	_	
12-23	2009-2019	nucleotide	_	_	
12-24	2020-2033	polymorphisms	_	_	
12-25	2033-2034	.	_	_	
12-26	2035-2036	[	_	_	
12-27	2036-2040	0061	_	_	
12-28	2040-2041	]	_	_	
12-29	2042-2043	A	_	_	
12-30	2044-2050	number	_	_	
12-31	2051-2053	of	_	_	
12-32	2054-2063	different	_	_	
12-33	2064-2071	methods	_	_	
12-34	2072-2074	of	_	_	
12-35	2075-2084	detecting	_	_	
12-36	2085-2091	single	_	_	
12-37	2092-2102	nucleotide	_	_	
12-38	2103-2116	polymorphisms	_	_	
12-39	2117-2120	are	_	_	
12-40	2121-2126	known	_	_	
12-41	2127-2129	in	_	_	
12-42	2130-2133	the	_	_	
12-43	2134-2139	prior	_	_	
12-44	2140-2143	art	_	_	
12-45	2143-2144	.	_	_	

#Text=As a rule methods are applied that are based on amplification of the region of the sequence of the patient's genomic DNA that contains the single nucleotide polymorphism.
13-1	2145-2147	As	*[1]	17-1[2_1]	
13-2	2148-2149	a	*[1]	_	
13-3	2150-2154	rule	*[1]	_	
13-4	2155-2162	methods	*[1]	_	
13-5	2163-2166	are	*[1]	_	
13-6	2167-2174	applied	*[1]	_	
13-7	2175-2179	that	*[1]	_	
13-8	2180-2183	are	*[1]	_	
13-9	2184-2189	based	*[1]	_	
13-10	2190-2192	on	*[1]	_	
13-11	2193-2206	amplification	*[1]	_	
13-12	2207-2209	of	*[1]	_	
13-13	2210-2213	the	*[1]	_	
13-14	2214-2220	region	*[1]	_	
13-15	2221-2223	of	*[1]	_	
13-16	2224-2227	the	*[1]	_	
13-17	2228-2236	sequence	*[1]	_	
13-18	2237-2239	of	*[1]	_	
13-19	2240-2243	the	*[1]	_	
13-20	2244-2253	patient's	*[1]	_	
13-21	2254-2261	genomic	*[1]	_	
13-22	2262-2265	DNA	*[1]	_	
13-23	2266-2270	that	*[1]	_	
13-24	2271-2279	contains	*[1]	_	
13-25	2280-2283	the	*[1]	_	
13-26	2284-2290	single	*[1]	_	
13-27	2291-2301	nucleotide	*[1]	_	
13-28	2302-2314	polymorphism	*[1]	_	
13-29	2314-2315	.	*[1]	_	

#Text=An elegant possibility for detecting a single nucleotide polymorphism was described by Langegren and Hood in U.S.
14-1	2316-2318	An	_	_	
14-2	2319-2326	elegant	_	_	
14-3	2327-2338	possibility	_	_	
14-4	2339-2342	for	_	_	
14-5	2343-2352	detecting	_	_	
14-6	2353-2354	a	_	_	
14-7	2355-2361	single	_	_	
14-8	2362-2372	nucleotide	_	_	
14-9	2373-2385	polymorphism	_	_	
14-10	2386-2389	was	_	_	
14-11	2390-2399	described	_	_	
14-12	2400-2402	by	_	_	
14-13	2403-2412	Langegren	_	_	
14-14	2413-2416	and	_	_	
14-15	2417-2421	Hood	_	_	
14-16	2422-2424	in	_	_	
14-17	2425-2428	U.S	_	_	
14-18	2428-2429	.	_	_	

#Text=Pat.
15-1	2430-2433	Pat	_	_	
15-2	2433-2434	.	_	_	

#Text=No. 4,988,617.
16-1	2435-2437	No	_	_	
16-2	2437-2438	.	_	_	
16-3	2439-2448	4,988,617	_	_	
16-4	2448-2449	.	_	_	

#Text=This method has become known in the field as ligation detection reaction (LDR).
17-1	2450-2454	This	*[2]	_	
17-2	2455-2461	method	*[2]	_	
17-3	2462-2465	has	_	_	
17-4	2466-2472	become	_	_	
17-5	2473-2478	known	_	_	
17-6	2479-2481	in	_	_	
17-7	2482-2485	the	_	_	
17-8	2486-2491	field	_	_	
17-9	2492-2494	as	_	_	
17-10	2495-2503	ligation	_	_	
17-11	2504-2513	detection	_	_	
17-12	2514-2522	reaction	_	_	
17-13	2523-2524	(	_	_	
17-14	2524-2527	LDR	_	_	
17-15	2527-2528	)	_	_	
17-16	2528-2529	.	_	_	

#Text=The method is based on the hybridization of two oligonucleotides to a target DNA sequence, wherein the two oligonucleotides hybridize immediately next to each other to the target DNA sequence and in a subsequent step are joined together by a ligase.
18-1	2530-2533	The	_	_	
18-2	2534-2540	method	_	_	
18-3	2541-2543	is	_	_	
18-4	2544-2549	based	_	_	
18-5	2550-2552	on	_	_	
18-6	2553-2556	the	_	_	
18-7	2557-2570	hybridization	_	_	
18-8	2571-2573	of	_	_	
18-9	2574-2577	two	_	_	
18-10	2578-2594	oligonucleotides	_	_	
18-11	2595-2597	to	_	_	
18-12	2598-2599	a	_	_	
18-13	2600-2606	target	_	_	
18-14	2607-2610	DNA	_	_	
18-15	2611-2619	sequence	_	_	
18-16	2619-2620	,	_	_	
18-17	2621-2628	wherein	_	_	
18-18	2629-2632	the	_	_	
18-19	2633-2636	two	_	_	
18-20	2637-2653	oligonucleotides	_	_	
18-21	2654-2663	hybridize	_	_	
18-22	2664-2675	immediately	_	_	
18-23	2676-2680	next	_	_	
18-24	2681-2683	to	_	_	
18-25	2684-2688	each	_	_	
18-26	2689-2694	other	_	_	
18-27	2695-2697	to	_	_	
18-28	2698-2701	the	_	_	
18-29	2702-2708	target	_	_	
18-30	2709-2712	DNA	_	_	
18-31	2713-2721	sequence	_	_	
18-32	2722-2725	and	_	_	
18-33	2726-2728	in	_	_	
18-34	2729-2730	a	_	_	
18-35	2731-2741	subsequent	_	_	
18-36	2742-2746	step	_	_	
18-37	2747-2750	are	_	_	
18-38	2751-2757	joined	_	_	
18-39	2758-2766	together	_	_	
18-40	2767-2769	by	_	_	
18-41	2770-2771	a	_	_	
18-42	2772-2778	ligase	_	_	
18-43	2778-2779	.	_	_	

#Text=The longer oligonucleotide formed as a result of ligation is detected by PCR, wherein formation of a PCR product only occurs if ligation of the two individual oligonucleotides has taken place.
19-1	2780-2783	The	_	_	
19-2	2784-2790	longer	_	_	
19-3	2791-2806	oligonucleotide	_	_	
19-4	2807-2813	formed	_	_	
19-5	2814-2816	as	_	_	
19-6	2817-2818	a	_	_	
19-7	2819-2825	result	_	_	
19-8	2826-2828	of	_	_	
19-9	2829-2837	ligation	_	_	
19-10	2838-2840	is	_	_	
19-11	2841-2849	detected	_	_	
19-12	2850-2852	by	_	_	
19-13	2853-2856	PCR	_	_	
19-14	2856-2857	,	_	_	
19-15	2858-2865	wherein	_	_	
19-16	2866-2875	formation	_	_	
19-17	2876-2878	of	_	_	
19-18	2879-2880	a	_	_	
19-19	2881-2884	PCR	_	_	
19-20	2885-2892	product	_	_	
19-21	2893-2897	only	_	_	
19-22	2898-2904	occurs	_	_	
19-23	2905-2907	if	_	_	
19-24	2908-2916	ligation	_	_	
19-25	2917-2919	of	_	_	
19-26	2920-2923	the	_	_	
19-27	2924-2927	two	_	_	
19-28	2928-2938	individual	_	_	
19-29	2939-2955	oligonucleotides	_	_	
19-30	2956-2959	has	_	_	
19-31	2960-2965	taken	_	_	
19-32	2966-2971	place	_	_	
19-33	2971-2972	.	_	_	

#Text=Such ligation in turn only occurs if there is complete base pairing with the target DNA sequence in the adjacent end regions of the oligonucleotides.
20-1	2973-2977	Such	_	_	
20-2	2978-2986	ligation	_	_	
20-3	2987-2989	in	_	_	
20-4	2990-2994	turn	_	_	
20-5	2995-2999	only	_	_	
20-6	3000-3006	occurs	_	_	
20-7	3007-3009	if	_	_	
20-8	3010-3015	there	_	_	
20-9	3016-3018	is	_	_	
20-10	3019-3027	complete	_	_	
20-11	3028-3032	base	_	_	
20-12	3033-3040	pairing	_	_	
20-13	3041-3045	with	_	_	
20-14	3046-3049	the	_	_	
20-15	3050-3056	target	_	_	
20-16	3057-3060	DNA	_	_	
20-17	3061-3069	sequence	_	_	
20-18	3070-3072	in	_	_	
20-19	3073-3076	the	_	_	
20-20	3077-3085	adjacent	_	_	
20-21	3086-3089	end	_	_	
20-22	3090-3097	regions	_	_	
20-23	3098-3100	of	_	_	
20-24	3101-3104	the	_	_	
20-25	3105-3121	oligonucleotides	_	_	
20-26	3121-3122	.	_	_	

#Text=If, however, there has been no base pairing with the target DNA sequence in this region of one of the nucleotides (for example owing to a single nucleotide polymorphism in the target DNA sequence), no ligation of the oligonucleotides occurs, and therefore no PCR product can be amplified.
21-1	3123-3125	If	_	_	
21-2	3125-3126	,	_	_	
21-3	3127-3134	however	_	_	
21-4	3134-3135	,	_	_	
21-5	3136-3141	there	_	_	
21-6	3142-3145	has	_	_	
21-7	3146-3150	been	_	_	
21-8	3151-3153	no	_	_	
21-9	3154-3158	base	_	_	
21-10	3159-3166	pairing	_	_	
21-11	3167-3171	with	_	_	
21-12	3172-3175	the	_	_	
21-13	3176-3182	target	_	_	
21-14	3183-3186	DNA	_	_	
21-15	3187-3195	sequence	_	_	
21-16	3196-3198	in	_	_	
21-17	3199-3203	this	_	_	
21-18	3204-3210	region	_	_	
21-19	3211-3213	of	_	_	
21-20	3214-3217	one	_	_	
21-21	3218-3220	of	_	_	
21-22	3221-3224	the	_	_	
21-23	3225-3236	nucleotides	_	_	
21-24	3237-3238	(	_	_	
21-25	3238-3241	for	_	_	
21-26	3242-3249	example	_	_	
21-27	3250-3255	owing	_	_	
21-28	3256-3258	to	_	_	
21-29	3259-3260	a	_	_	
21-30	3261-3267	single	_	_	
21-31	3268-3278	nucleotide	_	_	
21-32	3279-3291	polymorphism	_	_	
21-33	3292-3294	in	_	_	
21-34	3295-3298	the	_	_	
21-35	3299-3305	target	_	_	
21-36	3306-3309	DNA	_	_	
21-37	3310-3318	sequence	_	_	
21-38	3318-3319	)	_	_	
21-39	3319-3320	,	_	_	
21-40	3321-3323	no	_	_	
21-41	3324-3332	ligation	_	_	
21-42	3333-3335	of	_	_	
21-43	3336-3339	the	_	_	
21-44	3340-3356	oligonucleotides	_	_	
21-45	3357-3363	occurs	_	_	
21-46	3363-3364	,	_	_	
21-47	3365-3368	and	_	_	
21-48	3369-3378	therefore	_	_	
21-49	3379-3381	no	_	_	
21-50	3382-3385	PCR	_	_	
21-51	3386-3393	product	_	_	
21-52	3394-3397	can	_	_	
21-53	3398-3400	be	_	_	
21-54	3401-3410	amplified	_	_	
21-55	3410-3411	.	_	_	

#Text=Based on this principle, by using the labeled oligonucleotides according to the invention, it is possible to devise a rapid test that can provide information about the presence of the respective single nucleotide polymorphism within a few minutes, without having to resort to PCR or other expensive methods of detection.
#Text=[0062] According to a particular embodiment of the present invention, an in vitro method is therefore provided for the detection of a target DNA sequence from a group of DNA sequences, the members of which differ from one another in exactly one predetermined nucleotide position.
22-1	3412-3417	Based	_	_	
22-2	3418-3420	on	_	_	
22-3	3421-3425	this	_	_	
22-4	3426-3435	principle	_	_	
22-5	3435-3436	,	_	_	
22-6	3437-3439	by	_	_	
22-7	3440-3445	using	_	_	
22-8	3446-3449	the	_	_	
22-9	3450-3457	labeled	_	_	
22-10	3458-3474	oligonucleotides	_	_	
22-11	3475-3484	according	_	_	
22-12	3485-3487	to	_	_	
22-13	3488-3491	the	_	_	
22-14	3492-3501	invention	_	_	
22-15	3501-3502	,	_	_	
22-16	3503-3505	it	_	_	
22-17	3506-3508	is	_	_	
22-18	3509-3517	possible	_	_	
22-19	3518-3520	to	_	_	
22-20	3521-3527	devise	_	_	
22-21	3528-3529	a	_	_	
22-22	3530-3535	rapid	_	_	
22-23	3536-3540	test	_	_	
22-24	3541-3545	that	_	_	
22-25	3546-3549	can	_	_	
22-26	3550-3557	provide	_	_	
22-27	3558-3569	information	_	_	
22-28	3570-3575	about	_	_	
22-29	3576-3579	the	_	_	
22-30	3580-3588	presence	_	_	
22-31	3589-3591	of	_	_	
22-32	3592-3595	the	_	_	
22-33	3596-3606	respective	_	_	
22-34	3607-3613	single	_	_	
22-35	3614-3624	nucleotide	_	_	
22-36	3625-3637	polymorphism	_	_	
22-37	3638-3644	within	_	_	
22-38	3645-3646	a	_	_	
22-39	3647-3650	few	_	_	
22-40	3651-3658	minutes	_	_	
22-41	3658-3659	,	_	_	
22-42	3660-3667	without	_	_	
22-43	3668-3674	having	_	_	
22-44	3675-3677	to	_	_	
22-45	3678-3684	resort	_	_	
22-46	3685-3687	to	_	_	
22-47	3688-3691	PCR	_	_	
22-48	3692-3694	or	_	_	
22-49	3695-3700	other	_	_	
22-50	3701-3710	expensive	_	_	
22-51	3711-3718	methods	_	_	
22-52	3719-3721	of	_	_	
22-53	3722-3731	detection	_	_	
22-54	3731-3732	.	_	_	
22-55	3733-3734	[	_	_	
22-56	3734-3738	0062	_	_	
22-57	3738-3739	]	_	_	
22-58	3740-3749	According	_	_	
22-59	3750-3752	to	_	_	
22-60	3753-3754	a	_	_	
22-61	3755-3765	particular	_	_	
22-62	3766-3776	embodiment	_	_	
22-63	3777-3779	of	_	_	
22-64	3780-3783	the	_	_	
22-65	3784-3791	present	_	_	
22-66	3792-3801	invention	_	_	
22-67	3801-3802	,	_	_	
22-68	3803-3805	an	_	_	
22-69	3806-3808	in	_	_	
22-70	3809-3814	vitro	_	_	
22-71	3815-3821	method	_	_	
22-72	3822-3824	is	_	_	
22-73	3825-3834	therefore	_	_	
22-74	3835-3843	provided	_	_	
22-75	3844-3847	for	_	_	
22-76	3848-3851	the	_	_	
22-77	3852-3861	detection	_	_	
22-78	3862-3864	of	_	_	
22-79	3865-3866	a	_	_	
22-80	3867-3873	target	_	_	
22-81	3874-3877	DNA	_	_	
22-82	3878-3886	sequence	_	_	
22-83	3887-3891	from	_	_	
22-84	3892-3893	a	_	_	
22-85	3894-3899	group	_	_	
22-86	3900-3902	of	_	_	
22-87	3903-3906	DNA	_	_	
22-88	3907-3916	sequences	_	_	
22-89	3916-3917	,	_	_	
22-90	3918-3921	the	_	_	
22-91	3922-3929	members	_	_	
22-92	3930-3932	of	_	_	
22-93	3933-3938	which	_	_	
22-94	3939-3945	differ	_	_	
22-95	3946-3950	from	_	_	
22-96	3951-3954	one	_	_	
22-97	3955-3962	another	_	_	
22-98	3963-3965	in	_	_	
22-99	3966-3973	exactly	_	_	
22-100	3974-3977	one	_	_	
22-101	3978-3991	predetermined	_	_	
22-102	3992-4002	nucleotide	_	_	
22-103	4003-4011	position	_	_	
22-104	4011-4012	.	_	_	

#Text=The method comprises [0063](a) providing cells on a support, wherein at least a portion of the cells is lysed; [0064](b) contacting the cells on the support with a first and a second oligonucleotide, at least one of which is labeled with a beta-D-galactopyranoside, which on hydrolysis of the glycosidic bond forms a water-insoluble dye, and wherein said oligonucleotides are selected so that [0065](i) in each case they can hybridize by a terminal segment to the target DNA sequence, in such a way that the terminal nucleotides of the two terminal segments are arranged immediately adjacent to one another, wherein the nucleotide at the predetermined position of the target DNA sequence forms a complementary base pairing with a nucleotide in the terminal segment of the first oligonucleotide, and so that [0066](ii) on hybridization of the two terminal segments to another DNA sequence from the group of DNA sequences due to the absence of complementary base pairing between the nucleotide at the predetermined position of the DNA sequence and a nucleotide in the terminal segment of the first oligonucleotide, the terminal nucleotide of the terminal segment of the first oligonucleotide cannot hybridize to the DNA sequence, so that the terminal nucleotides of the two terminal segments are not arranged immediately adjacent to one another; [0067](c) incubating the two oligonucleotides under conditions that make hybridization of the two oligonucleotides to the target DNA sequence possible; [0068](d) contacting the two hybridized oligonucleotides with a ligating agent which only links them to form a ligation product if the two terminal nucleotides of the terminal segments are arranged immediately adjacent to one another; [0069](e) heating the reaction batch to a temperature at which labeled, nonligated oligonucleotides detach from the target DNA sequence, and at which the ligation product remains hybridized to the target DNA sequence; [0070](f) detecing the ligation product hybridized to the target DNA sequence by hydrolysis of the glycosidic bond of the beta-D-galactopyranoside; [0071]wherein the formation of a dye in the region of the cells on the support indicates the presence of the target DNA sequence in the cells.
#Text=[0072] The target DNA sequence to be detected is preferably the sequence of a gene or of a part of a gene.
23-1	4013-4016	The	_	_	
23-2	4017-4023	method	_	_	
23-3	4024-4033	comprises	_	_	
23-4	4034-4035	[	_	_	
23-5	4035-4039	0063	_	_	
23-6	4039-4040	]	_	_	
23-7	4040-4041	(	_	_	
23-8	4041-4042	a	_	_	
23-9	4042-4043	)	_	_	
23-10	4044-4053	providing	_	_	
23-11	4054-4059	cells	_	_	
23-12	4060-4062	on	_	_	
23-13	4063-4064	a	_	_	
23-14	4065-4072	support	_	_	
23-15	4072-4073	,	_	_	
23-16	4074-4081	wherein	_	_	
23-17	4082-4084	at	_	_	
23-18	4085-4090	least	_	_	
23-19	4091-4092	a	_	_	
23-20	4093-4100	portion	_	_	
23-21	4101-4103	of	_	_	
23-22	4104-4107	the	_	_	
23-23	4108-4113	cells	_	_	
23-24	4114-4116	is	_	_	
23-25	4117-4122	lysed	_	_	
23-26	4122-4123	;	_	_	
23-27	4124-4125	[	_	_	
23-28	4125-4129	0064	_	_	
23-29	4129-4130	]	_	_	
23-30	4130-4131	(	_	_	
23-31	4131-4132	b	_	_	
23-32	4132-4133	)	_	_	
23-33	4134-4144	contacting	_	_	
23-34	4145-4148	the	_	_	
23-35	4149-4154	cells	_	_	
23-36	4155-4157	on	_	_	
23-37	4158-4161	the	_	_	
23-38	4162-4169	support	_	_	
23-39	4170-4174	with	_	_	
23-40	4175-4176	a	_	_	
23-41	4177-4182	first	_	_	
23-42	4183-4186	and	_	_	
23-43	4187-4188	a	_	_	
23-44	4189-4195	second	_	_	
23-45	4196-4211	oligonucleotide	_	_	
23-46	4211-4212	,	_	_	
23-47	4213-4215	at	_	_	
23-48	4216-4221	least	_	_	
23-49	4222-4225	one	_	_	
23-50	4226-4228	of	_	_	
23-51	4229-4234	which	_	_	
23-52	4235-4237	is	_	_	
23-53	4238-4245	labeled	_	_	
23-54	4246-4250	with	_	_	
23-55	4251-4252	a	_	_	
23-56	4253-4277	beta-D-galactopyranoside	_	_	
23-57	4277-4278	,	_	_	
23-58	4279-4284	which	_	_	
23-59	4285-4287	on	_	_	
23-60	4288-4298	hydrolysis	_	_	
23-61	4299-4301	of	_	_	
23-62	4302-4305	the	_	_	
23-63	4306-4316	glycosidic	_	_	
23-64	4317-4321	bond	_	_	
23-65	4322-4327	forms	_	_	
23-66	4328-4329	a	_	_	
23-67	4330-4345	water-insoluble	_	_	
23-68	4346-4349	dye	_	_	
23-69	4349-4350	,	_	_	
23-70	4351-4354	and	_	_	
23-71	4355-4362	wherein	_	_	
23-72	4363-4367	said	_	_	
23-73	4368-4384	oligonucleotides	_	_	
23-74	4385-4388	are	_	_	
23-75	4389-4397	selected	_	_	
23-76	4398-4400	so	_	_	
23-77	4401-4405	that	_	_	
23-78	4406-4407	[	_	_	
23-79	4407-4411	0065	_	_	
23-80	4411-4412	]	_	_	
23-81	4412-4413	(	_	_	
23-82	4413-4414	i	_	_	
23-83	4414-4415	)	_	_	
23-84	4416-4418	in	_	_	
23-85	4419-4423	each	_	_	
23-86	4424-4428	case	_	_	
23-87	4429-4433	they	_	_	
23-88	4434-4437	can	_	_	
23-89	4438-4447	hybridize	_	_	
23-90	4448-4450	by	_	_	
23-91	4451-4452	a	_	_	
23-92	4453-4461	terminal	_	_	
23-93	4462-4469	segment	_	_	
23-94	4470-4472	to	_	_	
23-95	4473-4476	the	_	_	
23-96	4477-4483	target	_	_	
23-97	4484-4487	DNA	_	_	
23-98	4488-4496	sequence	_	_	
23-99	4496-4497	,	_	_	
23-100	4498-4500	in	_	_	
23-101	4501-4505	such	_	_	
23-102	4506-4507	a	_	_	
23-103	4508-4511	way	_	_	
23-104	4512-4516	that	_	_	
23-105	4517-4520	the	_	_	
23-106	4521-4529	terminal	_	_	
23-107	4530-4541	nucleotides	_	_	
23-108	4542-4544	of	_	_	
23-109	4545-4548	the	_	_	
23-110	4549-4552	two	_	_	
23-111	4553-4561	terminal	_	_	
23-112	4562-4570	segments	_	_	
23-113	4571-4574	are	_	_	
23-114	4575-4583	arranged	_	_	
23-115	4584-4595	immediately	_	_	
23-116	4596-4604	adjacent	_	_	
23-117	4605-4607	to	_	_	
23-118	4608-4611	one	_	_	
23-119	4612-4619	another	_	_	
23-120	4619-4620	,	_	_	
23-121	4621-4628	wherein	_	_	
23-122	4629-4632	the	_	_	
23-123	4633-4643	nucleotide	_	_	
23-124	4644-4646	at	_	_	
23-125	4647-4650	the	_	_	
23-126	4651-4664	predetermined	_	_	
23-127	4665-4673	position	_	_	
23-128	4674-4676	of	_	_	
23-129	4677-4680	the	_	_	
23-130	4681-4687	target	_	_	
23-131	4688-4691	DNA	_	_	
23-132	4692-4700	sequence	_	_	
23-133	4701-4706	forms	_	_	
23-134	4707-4708	a	_	_	
23-135	4709-4722	complementary	_	_	
23-136	4723-4727	base	_	_	
23-137	4728-4735	pairing	_	_	
23-138	4736-4740	with	_	_	
23-139	4741-4742	a	_	_	
23-140	4743-4753	nucleotide	_	_	
23-141	4754-4756	in	_	_	
23-142	4757-4760	the	_	_	
23-143	4761-4769	terminal	_	_	
23-144	4770-4777	segment	_	_	
23-145	4778-4780	of	_	_	
23-146	4781-4784	the	_	_	
23-147	4785-4790	first	_	_	
23-148	4791-4806	oligonucleotide	_	_	
23-149	4806-4807	,	_	_	
23-150	4808-4811	and	_	_	
23-151	4812-4814	so	_	_	
23-152	4815-4819	that	_	_	
23-153	4820-4821	[	_	_	
23-154	4821-4825	0066	_	_	
23-155	4825-4826	]	_	_	
23-156	4826-4827	(	_	_	
23-157	4827-4829	ii	_	_	
23-158	4829-4830	)	_	_	
23-159	4831-4833	on	_	_	
23-160	4834-4847	hybridization	_	_	
23-161	4848-4850	of	_	_	
23-162	4851-4854	the	_	_	
23-163	4855-4858	two	_	_	
23-164	4859-4867	terminal	_	_	
23-165	4868-4876	segments	_	_	
23-166	4877-4879	to	_	_	
23-167	4880-4887	another	_	_	
23-168	4888-4891	DNA	_	_	
23-169	4892-4900	sequence	_	_	
23-170	4901-4905	from	_	_	
23-171	4906-4909	the	_	_	
23-172	4910-4915	group	_	_	
23-173	4916-4918	of	_	_	
23-174	4919-4922	DNA	_	_	
23-175	4923-4932	sequences	_	_	
23-176	4933-4936	due	_	_	
23-177	4937-4939	to	_	_	
23-178	4940-4943	the	_	_	
23-179	4944-4951	absence	_	_	
23-180	4952-4954	of	_	_	
23-181	4955-4968	complementary	_	_	
23-182	4969-4973	base	_	_	
23-183	4974-4981	pairing	_	_	
23-184	4982-4989	between	_	_	
23-185	4990-4993	the	_	_	
23-186	4994-5004	nucleotide	_	_	
23-187	5005-5007	at	_	_	
23-188	5008-5011	the	_	_	
23-189	5012-5025	predetermined	_	_	
23-190	5026-5034	position	_	_	
23-191	5035-5037	of	_	_	
23-192	5038-5041	the	_	_	
23-193	5042-5045	DNA	_	_	
23-194	5046-5054	sequence	_	_	
23-195	5055-5058	and	_	_	
23-196	5059-5060	a	_	_	
23-197	5061-5071	nucleotide	_	_	
23-198	5072-5074	in	_	_	
23-199	5075-5078	the	_	_	
23-200	5079-5087	terminal	_	_	
23-201	5088-5095	segment	_	_	
23-202	5096-5098	of	_	_	
23-203	5099-5102	the	_	_	
23-204	5103-5108	first	_	_	
23-205	5109-5124	oligonucleotide	_	_	
23-206	5124-5125	,	_	_	
23-207	5126-5129	the	_	_	
23-208	5130-5138	terminal	_	_	
23-209	5139-5149	nucleotide	_	_	
23-210	5150-5152	of	_	_	
23-211	5153-5156	the	_	_	
23-212	5157-5165	terminal	_	_	
23-213	5166-5173	segment	_	_	
23-214	5174-5176	of	_	_	
23-215	5177-5180	the	_	_	
23-216	5181-5186	first	_	_	
23-217	5187-5202	oligonucleotide	_	_	
23-218	5203-5209	cannot	_	_	
23-219	5210-5219	hybridize	_	_	
23-220	5220-5222	to	_	_	
23-221	5223-5226	the	_	_	
23-222	5227-5230	DNA	_	_	
23-223	5231-5239	sequence	_	_	
23-224	5239-5240	,	_	_	
23-225	5241-5243	so	_	_	
23-226	5244-5248	that	_	_	
23-227	5249-5252	the	_	_	
23-228	5253-5261	terminal	_	_	
23-229	5262-5273	nucleotides	_	_	
23-230	5274-5276	of	_	_	
23-231	5277-5280	the	_	_	
23-232	5281-5284	two	_	_	
23-233	5285-5293	terminal	_	_	
23-234	5294-5302	segments	_	_	
23-235	5303-5306	are	_	_	
23-236	5307-5310	not	_	_	
23-237	5311-5319	arranged	_	_	
23-238	5320-5331	immediately	_	_	
23-239	5332-5340	adjacent	_	_	
23-240	5341-5343	to	_	_	
23-241	5344-5347	one	_	_	
23-242	5348-5355	another	_	_	
23-243	5355-5356	;	_	_	
23-244	5357-5358	[	_	_	
23-245	5358-5362	0067	_	_	
23-246	5362-5363	]	_	_	
23-247	5363-5364	(	_	_	
23-248	5364-5365	c	_	_	
23-249	5365-5366	)	_	_	
23-250	5367-5377	incubating	_	_	
23-251	5378-5381	the	_	_	
23-252	5382-5385	two	_	_	
23-253	5386-5402	oligonucleotides	_	_	
23-254	5403-5408	under	_	_	
23-255	5409-5419	conditions	_	_	
23-256	5420-5424	that	_	_	
23-257	5425-5429	make	_	_	
23-258	5430-5443	hybridization	_	_	
23-259	5444-5446	of	_	_	
23-260	5447-5450	the	_	_	
23-261	5451-5454	two	_	_	
23-262	5455-5471	oligonucleotides	_	_	
23-263	5472-5474	to	_	_	
23-264	5475-5478	the	_	_	
23-265	5479-5485	target	_	_	
23-266	5486-5489	DNA	_	_	
23-267	5490-5498	sequence	_	_	
23-268	5499-5507	possible	_	_	
23-269	5507-5508	;	_	_	
23-270	5509-5510	[	_	_	
23-271	5510-5514	0068	_	_	
23-272	5514-5515	]	_	_	
23-273	5515-5516	(	_	_	
23-274	5516-5517	d	_	_	
23-275	5517-5518	)	_	_	
23-276	5519-5529	contacting	_	_	
23-277	5530-5533	the	_	_	
23-278	5534-5537	two	_	_	
23-279	5538-5548	hybridized	_	_	
23-280	5549-5565	oligonucleotides	_	_	
23-281	5566-5570	with	_	_	
23-282	5571-5572	a	_	_	
23-283	5573-5581	ligating	_	_	
23-284	5582-5587	agent	_	_	
23-285	5588-5593	which	_	_	
23-286	5594-5598	only	_	_	
23-287	5599-5604	links	_	_	
23-288	5605-5609	them	_	_	
23-289	5610-5612	to	_	_	
23-290	5613-5617	form	_	_	
23-291	5618-5619	a	_	_	
23-292	5620-5628	ligation	_	_	
23-293	5629-5636	product	_	_	
23-294	5637-5639	if	_	_	
23-295	5640-5643	the	_	_	
23-296	5644-5647	two	_	_	
23-297	5648-5656	terminal	_	_	
23-298	5657-5668	nucleotides	_	_	
23-299	5669-5671	of	_	_	
23-300	5672-5675	the	_	_	
23-301	5676-5684	terminal	_	_	
23-302	5685-5693	segments	_	_	
23-303	5694-5697	are	_	_	
23-304	5698-5706	arranged	_	_	
23-305	5707-5718	immediately	_	_	
23-306	5719-5727	adjacent	_	_	
23-307	5728-5730	to	_	_	
23-308	5731-5734	one	_	_	
23-309	5735-5742	another	_	_	
23-310	5742-5743	;	_	_	
23-311	5744-5745	[	_	_	
23-312	5745-5749	0069	_	_	
23-313	5749-5750	]	_	_	
23-314	5750-5751	(	_	_	
23-315	5751-5752	e	_	_	
23-316	5752-5753	)	_	_	
23-317	5754-5761	heating	_	_	
23-318	5762-5765	the	_	_	
23-319	5766-5774	reaction	_	_	
23-320	5775-5780	batch	_	_	
23-321	5781-5783	to	_	_	
23-322	5784-5785	a	_	_	
23-323	5786-5797	temperature	_	_	
23-324	5798-5800	at	_	_	
23-325	5801-5806	which	_	_	
23-326	5807-5814	labeled	_	_	
23-327	5814-5815	,	_	_	
23-328	5816-5826	nonligated	_	_	
23-329	5827-5843	oligonucleotides	_	_	
23-330	5844-5850	detach	_	_	
23-331	5851-5855	from	_	_	
23-332	5856-5859	the	_	_	
23-333	5860-5866	target	_	_	
23-334	5867-5870	DNA	_	_	
23-335	5871-5879	sequence	_	_	
23-336	5879-5880	,	_	_	
23-337	5881-5884	and	_	_	
23-338	5885-5887	at	_	_	
23-339	5888-5893	which	_	_	
23-340	5894-5897	the	_	_	
23-341	5898-5906	ligation	_	_	
23-342	5907-5914	product	_	_	
23-343	5915-5922	remains	_	_	
23-344	5923-5933	hybridized	_	_	
23-345	5934-5936	to	_	_	
23-346	5937-5940	the	_	_	
23-347	5941-5947	target	_	_	
23-348	5948-5951	DNA	_	_	
23-349	5952-5960	sequence	_	_	
23-350	5960-5961	;	_	_	
23-351	5962-5963	[	_	_	
23-352	5963-5967	0070	_	_	
23-353	5967-5968	]	_	_	
23-354	5968-5969	(	_	_	
23-355	5969-5970	f	_	_	
23-356	5970-5971	)	_	_	
23-357	5972-5980	detecing	_	_	
23-358	5981-5984	the	_	_	
23-359	5985-5993	ligation	_	_	
23-360	5994-6001	product	_	_	
23-361	6002-6012	hybridized	_	_	
23-362	6013-6015	to	_	_	
23-363	6016-6019	the	_	_	
23-364	6020-6026	target	_	_	
23-365	6027-6030	DNA	_	_	
23-366	6031-6039	sequence	_	_	
23-367	6040-6042	by	_	_	
23-368	6043-6053	hydrolysis	_	_	
23-369	6054-6056	of	_	_	
23-370	6057-6060	the	_	_	
23-371	6061-6071	glycosidic	_	_	
23-372	6072-6076	bond	_	_	
23-373	6077-6079	of	_	_	
23-374	6080-6083	the	_	_	
23-375	6084-6108	beta-D-galactopyranoside	_	_	
23-376	6108-6109	;	_	_	
23-377	6110-6111	[	_	_	
23-378	6111-6115	0071	_	_	
23-379	6115-6116	]	_	_	
23-380	6116-6123	wherein	_	_	
23-381	6124-6127	the	_	_	
23-382	6128-6137	formation	_	_	
23-383	6138-6140	of	_	_	
23-384	6141-6142	a	_	_	
23-385	6143-6146	dye	_	_	
23-386	6147-6149	in	_	_	
23-387	6150-6153	the	_	_	
23-388	6154-6160	region	_	_	
23-389	6161-6163	of	_	_	
23-390	6164-6167	the	_	_	
23-391	6168-6173	cells	_	_	
23-392	6174-6176	on	_	_	
23-393	6177-6180	the	_	_	
23-394	6181-6188	support	_	_	
23-395	6189-6198	indicates	_	_	
23-396	6199-6202	the	_	_	
23-397	6203-6211	presence	_	_	
23-398	6212-6214	of	_	_	
23-399	6215-6218	the	_	_	
23-400	6219-6225	target	_	_	
23-401	6226-6229	DNA	_	_	
23-402	6230-6238	sequence	_	_	
23-403	6239-6241	in	_	_	
23-404	6242-6245	the	_	_	
23-405	6246-6251	cells	_	_	
23-406	6251-6252	.	_	_	
23-407	6253-6254	[	_	_	
23-408	6254-6258	0072	_	_	
23-409	6258-6259	]	_	_	
23-410	6260-6263	The	_	_	
23-411	6264-6270	target	_	_	
23-412	6271-6274	DNA	_	_	
23-413	6275-6283	sequence	_	_	
23-414	6284-6286	to	_	_	
23-415	6287-6289	be	_	_	
23-416	6290-6298	detected	_	_	
23-417	6299-6301	is	_	_	
23-418	6302-6312	preferably	_	_	
23-419	6313-6316	the	_	_	
23-420	6317-6325	sequence	_	_	
23-421	6326-6328	of	_	_	
23-422	6329-6330	a	_	_	
23-423	6331-6335	gene	_	_	
23-424	6336-6338	or	_	_	
23-425	6339-6341	of	_	_	
23-426	6342-6343	a	_	_	
23-427	6344-6348	part	_	_	
23-428	6349-6351	of	_	_	
23-429	6352-6353	a	_	_	
23-430	6354-6358	gene	_	_	
23-431	6358-6359	.	_	_	

#Text=According to an particularly preferred embodiment it is the sequence of a human gene or of a part thereof.
24-1	6360-6369	According	_	_	
24-2	6370-6372	to	_	_	
24-3	6373-6375	an	_	_	
24-4	6376-6388	particularly	_	_	
24-5	6389-6398	preferred	_	_	
24-6	6399-6409	embodiment	_	_	
24-7	6410-6412	it	_	_	
24-8	6413-6415	is	_	_	
24-9	6416-6419	the	_	_	
24-10	6420-6428	sequence	_	_	
24-11	6429-6431	of	_	_	
24-12	6432-6433	a	_	_	
24-13	6434-6439	human	_	_	
24-14	6440-6444	gene	_	_	
24-15	6445-6447	or	_	_	
24-16	6448-6450	of	_	_	
24-17	6451-6452	a	_	_	
24-18	6453-6457	part	_	_	
24-19	6458-6465	thereof	_	_	
24-20	6465-6466	.	_	_	

#Text=According to the invention the target DNA sequence is known completely or partially.
25-1	6467-6476	According	_	_	
25-2	6477-6479	to	_	_	
25-3	6480-6483	the	_	_	
25-4	6484-6493	invention	_	_	
25-5	6494-6497	the	_	_	
25-6	6498-6504	target	_	_	
25-7	6505-6508	DNA	_	_	
25-8	6509-6517	sequence	_	_	
25-9	6518-6520	is	_	_	
25-10	6521-6526	known	_	_	
25-11	6527-6537	completely	_	_	
25-12	6538-6540	or	_	_	
25-13	6541-6550	partially	_	_	
25-14	6550-6551	.	_	_	

#Text=This means that at least the region around the predetermined nucleotide position is known with respect to its nucleotide or base sequence, so that corresponding oligonucleotides can be prepared for hybridization to this region.
26-1	6552-6556	This	_	_	
26-2	6557-6562	means	_	_	
26-3	6563-6567	that	_	_	
26-4	6568-6570	at	_	_	
26-5	6571-6576	least	_	_	
26-6	6577-6580	the	_	_	
26-7	6581-6587	region	_	_	
26-8	6588-6594	around	_	_	
26-9	6595-6598	the	_	_	
26-10	6599-6612	predetermined	_	_	
26-11	6613-6623	nucleotide	_	_	
26-12	6624-6632	position	_	_	
26-13	6633-6635	is	_	_	
26-14	6636-6641	known	_	_	
26-15	6642-6646	with	_	_	
26-16	6647-6654	respect	_	_	
26-17	6655-6657	to	_	_	
26-18	6658-6661	its	_	_	
26-19	6662-6672	nucleotide	_	_	
26-20	6673-6675	or	_	_	
26-21	6676-6680	base	_	_	
26-22	6681-6689	sequence	_	_	
26-23	6689-6690	,	_	_	
26-24	6691-6693	so	_	_	
26-25	6694-6698	that	_	_	
26-26	6699-6712	corresponding	_	_	
26-27	6713-6729	oligonucleotides	_	_	
26-28	6730-6733	can	_	_	
26-29	6734-6736	be	_	_	
26-30	6737-6745	prepared	_	_	
26-31	6746-6749	for	_	_	
26-32	6750-6763	hybridization	_	_	
26-33	6764-6766	to	_	_	
26-34	6767-6771	this	_	_	
26-35	6772-6778	region	_	_	
26-36	6778-6779	.	_	_	

#Text=The method serves for distinguishing the target DNA sequence from other DNA sequences that differ in at least one, preferably in exactly one predetermined nucleotide position (i.e. by one base) from the target DNA sequence.
27-1	6780-6783	The	_	_	
27-2	6784-6790	method	_	_	
27-3	6791-6797	serves	_	_	
27-4	6798-6801	for	_	_	
27-5	6802-6816	distinguishing	_	_	
27-6	6817-6820	the	_	_	
27-7	6821-6827	target	_	_	
27-8	6828-6831	DNA	_	_	
27-9	6832-6840	sequence	_	_	
27-10	6841-6845	from	_	_	
27-11	6846-6851	other	_	_	
27-12	6852-6855	DNA	_	_	
27-13	6856-6865	sequences	_	_	
27-14	6866-6870	that	_	_	
27-15	6871-6877	differ	_	_	
27-16	6878-6880	in	_	_	
27-17	6881-6883	at	_	_	
27-18	6884-6889	least	_	_	
27-19	6890-6893	one	_	_	
27-20	6893-6894	,	_	_	
27-21	6895-6905	preferably	_	_	
27-22	6906-6908	in	_	_	
27-23	6909-6916	exactly	_	_	
27-24	6917-6920	one	_	_	
27-25	6921-6934	predetermined	_	_	
27-26	6935-6945	nucleotide	_	_	
27-27	6946-6954	position	_	_	
27-28	6955-6956	(	_	_	
27-29	6956-6959	i.e	_	_	
27-30	6959-6960	.	_	_	
27-31	6961-6963	by	_	_	
27-32	6964-6967	one	_	_	
27-33	6968-6972	base	_	_	
27-34	6972-6973	)	_	_	
27-35	6974-6978	from	_	_	
27-36	6979-6982	the	_	_	
27-37	6983-6989	target	_	_	
27-38	6990-6993	DNA	_	_	
27-39	6994-7002	sequence	_	_	
27-40	7002-7003	.	_	_	

#Text=The term "predetermined" means in this context that the position at which the various DNA sequences differ from one another is known with respect to its localization in the DNA sequences.
28-1	7004-7007	The	_	_	
28-2	7008-7012	term	_	_	
28-3	7013-7014	"	_	_	
28-4	7014-7027	predetermined	_	_	
28-5	7027-7028	"	_	_	
28-6	7029-7034	means	_	_	
28-7	7035-7037	in	_	_	
28-8	7038-7042	this	_	_	
28-9	7043-7050	context	_	_	
28-10	7051-7055	that	_	_	
28-11	7056-7059	the	_	_	
28-12	7060-7068	position	_	_	
28-13	7069-7071	at	_	_	
28-14	7072-7077	which	_	_	
28-15	7078-7081	the	_	_	
28-16	7082-7089	various	_	_	
28-17	7090-7093	DNA	_	_	
28-18	7094-7103	sequences	_	_	
28-19	7104-7110	differ	_	_	
28-20	7111-7115	from	_	_	
28-21	7116-7119	one	_	_	
28-22	7120-7127	another	_	_	
28-23	7128-7130	is	_	_	
28-24	7131-7136	known	_	_	
28-25	7137-7141	with	_	_	
28-26	7142-7149	respect	_	_	
28-27	7150-7152	to	_	_	
28-28	7153-7156	its	_	_	
28-29	7157-7169	localization	_	_	
28-30	7170-7172	in	_	_	
28-31	7173-7176	the	_	_	
28-32	7177-7180	DNA	_	_	
28-33	7181-7190	sequences	_	_	
28-34	7190-7191	.	_	_	

#Text=The target DNA sequence preferably has a length of about 20-20000 nucleotides, where a length of about 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 1000, 5000 or 10000 nucleotides is particularly preferred.
29-1	7192-7195	The	_	_	
29-2	7196-7202	target	_	_	
29-3	7203-7206	DNA	_	_	
29-4	7207-7215	sequence	_	_	
29-5	7216-7226	preferably	_	_	
29-6	7227-7230	has	_	_	
29-7	7231-7232	a	_	_	
29-8	7233-7239	length	_	_	
29-9	7240-7242	of	_	_	
29-10	7243-7248	about	_	_	
29-11	7249-7251	20	_	_	
29-12	7251-7252	-	_	_	
29-13	7252-7257	20000	_	_	
29-14	7258-7269	nucleotides	_	_	
29-15	7269-7270	,	_	_	
29-16	7271-7276	where	_	_	
29-17	7277-7278	a	_	_	
29-18	7279-7285	length	_	_	
29-19	7286-7288	of	_	_	
29-20	7289-7294	about	_	_	
29-21	7295-7297	50	_	_	
29-22	7297-7298	,	_	_	
29-23	7299-7301	60	_	_	
29-24	7301-7302	,	_	_	
29-25	7303-7305	70	_	_	
29-26	7305-7306	,	_	_	
29-27	7307-7309	80	_	_	
29-28	7309-7310	,	_	_	
29-29	7311-7313	90	_	_	
29-30	7313-7314	,	_	_	
29-31	7315-7318	100	_	_	
29-32	7318-7319	,	_	_	
29-33	7320-7323	200	_	_	
29-34	7323-7324	,	_	_	
29-35	7325-7328	300	_	_	
29-36	7328-7329	,	_	_	
29-37	7330-7333	400	_	_	
29-38	7333-7334	,	_	_	
29-39	7335-7338	500	_	_	
29-40	7338-7339	,	_	_	
29-41	7340-7343	600	_	_	
29-42	7343-7344	,	_	_	
29-43	7345-7349	1000	_	_	
29-44	7349-7350	,	_	_	
29-45	7351-7355	5000	_	_	
29-46	7356-7358	or	_	_	
29-47	7359-7364	10000	_	_	
29-48	7365-7376	nucleotides	_	_	
29-49	7377-7379	is	_	_	
29-50	7380-7392	particularly	_	_	
29-51	7393-7402	preferred	_	_	
29-52	7402-7403	.	_	_	
